<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548642" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548642/" /><meta name="ncbi_pagename" content="Angiotensin II Receptor Antagonists - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Angiotensin II Receptor Antagonists - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Angiotensin II Receptor Antagonists" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2017/01/13" /><meta name="citation_pmid" content="31643954" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548642/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Angiotensin II Receptor Antagonists" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2017/01/13" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548642/" /><meta name="description" content="The angiotensin II receptor antagonists, also known as angiotensin receptor blockers (ARBs), are a family of agents that bind to and inhibit the angiotensin II type 1 receptor (AT1) and thus inhibit the renin-angiotensin system and its cascade of effects in causing arteriolar contraction and sodium retention. While angiotensin converting enzyme (ACE) inhibitors block the cleavage of angiotensin I to angiotensin II, the active peptide that causes a pressor response, the ARBs inhibit its peripheral action. The ARBs reduce blood pressure in animal models as well as in humans. Since their introduction in 1995, these agents have been used widely in the therapy of hypertension and to reduce the complications of hypertensive cardiovascular disease and diabetic nephropathy." /><meta name="og:title" content="Angiotensin II Receptor Antagonists" /><meta name="og:type" content="book" /><meta name="og:description" content="The angiotensin II receptor antagonists, also known as angiotensin receptor blockers (ARBs), are a family of agents that bind to and inhibit the angiotensin II type 1 receptor (AT1) and thus inhibit the renin-angiotensin system and its cascade of effects in causing arteriolar contraction and sodium retention. While angiotensin converting enzyme (ACE) inhibitors block the cleavage of angiotensin I to angiotensin II, the active peptide that causes a pressor response, the ARBs inhibit its peripheral action. The ARBs reduce blood pressure in animal models as well as in humans. Since their introduction in 1995, these agents have been used widely in the therapy of hypertension and to reduce the complications of hypertensive cardiovascular disease and diabetic nephropathy." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548642/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/ARBs/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548642/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE899CA6046738D10000000000A9003C.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548642_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548642_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/GeneralAnesthetics/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/ACEinibitors/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548642_"><span class="title" itemprop="name">Angiotensin II Receptor Antagonists</span></h1><p class="small">Last Update: <span itemprop="dateModified">January 13, 2017</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="ARBs.OVERVIEW"><h2 id="_ARBs_OVERVIEW_">OVERVIEW</h2><p>The angiotensin II receptor antagonists, also known as angiotensin receptor blockers (ARBs), are a family of agents that bind to and inhibit the angiotensin II type 1 receptor (AT1) and thus inhibit the renin-angiotensin system and its cascade of effects in causing arteriolar contraction and sodium retention. While angiotensin converting enzyme (ACE) inhibitors block the cleavage of angiotensin I to angiotensin II, the active peptide that causes a pressor response, the ARBs inhibit its peripheral action. The ARBs reduce blood pressure in animal models as well as in humans. Since their introduction in 1995, these agents have been used widely in the therapy of hypertension and to reduce the complications of hypertensive cardiovascular disease and diabetic nephropathy.</p><p>The ARBs in clinical use in the United States include eight agents of similar chemical structure and activity, but somewhat different pharmacokinetics: losartan (Cozaar: 1995), valsartan (Diovan: 1996), irbesartan (Avapro: 1997), eprosartan (Teveten: 1997), candesartan (Atacand: 1998), telmisartan (Micardis: 1998), olmesartan (Benicar: 2002) and azilsartan (Edarbi: 2011). All of these agents have been associated with a minimal rate of serum enzyme elevations during chronic therapy (0.2% to 2%) which are usually mild-to-moderate in severity, self limited, and rarely require dose modification or discontinuation. As a class, the ARBs have been associated with rare instances of acute liver injury that is usually self limited in duration, but varies in clinical expression, being usually hepatocellular but occasional cholestatic in nature. The most common presentation of liver injury due to these agents is a cholestatic hepatitis arising within 1 to 8 weeks of starting and resolving as rapidly with stopping. Rare instances of prolonged jaundice have been described but not acute liver failure or autoimmune chronic hepatitis. Several Individual case reports of clinically apparent liver injury have been published in the literature for losartan, valsartan, irbesartan olmesartan and candesartan, but not specifically for azilsartan, eprosartan, and telmisartan, probably because these three have been in use for a shorter period of time and in fewer subjects.</p><p>Most ARBs and particularly olmesartan have been linked to rare instances of severe sprue-like enteropathy. The enteropathy typically presents with severe diarrhea and weight loss with variable degrees of fatigue, nausea and abdominal discomfort arising 6 months to many years after starting the ARB. Small intestinal histological findings resemble those of celiac disease with flattening of the duodenal villuous pattern and villous atrophy. However, anti-transglutaminase and endomysial antibodies (the serologic markers of celiac disease) are negative and there is little or no response to a gluten-free diet. Withdrawal of the ARB, however, results in prompt improvement in the diarrhea and gradual resolution of duodenal villous flattening. Some cases of this drug induced enteropathy have had accompanying serum aminotransferase elevations and fatty liver by imaging or liver biopsy, which, along with the diarrhea, resolve rapidly with stopping the medication.</p><p>The different angiotensin II receptor antagonists are discussed separately, but references on their hepatotoxicity are given together after this introductory section.</p><p>The following links are to individual drug records.</p><ul><li class="half_rhythm"><div><a href="/books/n/livertox/Azilsartan/">Azilsartan</a></div></li><li class="half_rhythm"><div><a href="/books/n/livertox/Candesartan/">Candesartan</a></div></li><li class="half_rhythm"><div><a href="/books/n/livertox/Eprosartan/">Eprosartan</a></div></li><li class="half_rhythm"><div><a href="/books/n/livertox/Irbesartan/">Irbesartan</a></div></li><li class="half_rhythm"><div><a href="/books/n/livertox/Losartan/">Losartan</a></div></li><li class="half_rhythm"><div><a href="/books/n/livertox/Olmesartan/">Olmesartan</a></div></li><li class="half_rhythm"><div><a href="/books/n/livertox/Telmisartan/">Telmisartan</a></div></li><li class="half_rhythm"><div><a href="/books/n/livertox/Valsartan/">Valsartan</a></div></li></ul></div><div id="ARBs.CHEMICAL_FORMULAS_AND_STRUCTURES"><h2 id="_ARBs_CHEMICAL_FORMULAS_AND_STRUCTURES_">CHEMICAL FORMULAS AND STRUCTURES</h2><div id="ARBs.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548642/table/ARBs.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ARBs.T1_lrgtbl__"><table><tbody><tr><th id="hd_b_ARBs.T1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">DRUG</th><th id="hd_b_ARBs.T1_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CAS REGISTRY NO.</th><th id="hd_b_ARBs.T1_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_b_ARBs.T1_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">STRUCTURE</th></tr><tr><td headers="hd_b_ARBs.T1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Azilsartan</td><td headers="hd_b_ARBs.T1_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">147403-03-0</td><td headers="hd_b_ARBs.T1_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">C25-H20-N4-O5</td><td headers="hd_b_ARBs.T1_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><div class="graphic"><img src="/books/NBK548642/bin/Azilsartan_Structure_000.jpg" alt="Azilsartan Chemical Structure" /></div></td></tr><tr><td headers="hd_b_ARBs.T1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Candesartan</td><td headers="hd_b_ARBs.T1_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135023846" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">139481-59-7</a></td><td headers="hd_b_ARBs.T1_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">C24-H20-N6-O3</td><td headers="hd_b_ARBs.T1_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><div class="graphic"><img src="/books/NBK548642/bin/Candesartan_Structure_000.jpg" alt="Chemical Structure for Candesartan" /></div></td></tr><tr><td headers="hd_b_ARBs.T1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Eprosartan</td><td headers="hd_b_ARBs.T1_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135026481" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">133040-01-4</a></td><td headers="hd_b_ARBs.T1_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">C23-H24-N2-O4-S</td><td headers="hd_b_ARBs.T1_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><div class="graphic"><img src="/books/NBK548642/bin/Eprosartan_Structure_000.jpg" alt="Chemical Structure for Eprosartan" /></div></td></tr><tr><td headers="hd_b_ARBs.T1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Irbesartan</td><td headers="hd_b_ARBs.T1_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135017843" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">138402-11-6</a></td><td headers="hd_b_ARBs.T1_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">C25-H28-N6-O</td><td headers="hd_b_ARBs.T1_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><div class="graphic"><img src="/books/NBK548642/bin/Irbesartan_Structure_000.jpg" alt="Chemical Structure for Irbesartan" /></div></td></tr><tr><td headers="hd_b_ARBs.T1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Losartan</td><td headers="hd_b_ARBs.T1_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">124750-99-8</td><td headers="hd_b_ARBs.T1_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">C22-H23-Cl-N6-O.K</td><td headers="hd_b_ARBs.T1_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><div class="graphic"><img src="/books/NBK548642/bin/Losartan_Structure_000.jpg" alt="Chemical Structure for Losartan" /></div></td></tr><tr><td headers="hd_b_ARBs.T1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Olmesartan</td><td headers="hd_b_ARBs.T1_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135114358" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">144689-24-7</a></td><td headers="hd_b_ARBs.T1_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">C24-H26-N6-O3</td><td headers="hd_b_ARBs.T1_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><div class="graphic"><img src="/books/NBK548642/bin/Olmesartan_Structure_001.jpg" alt="Chemical Structure for Olmesartan" /></div></td></tr><tr><td headers="hd_b_ARBs.T1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Telmisartan</td><td headers="hd_b_ARBs.T1_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135024022" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">144701-48-4</a></td><td headers="hd_b_ARBs.T1_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">C33-H30-N4-O2</td><td headers="hd_b_ARBs.T1_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><div class="graphic"><img src="/books/NBK548642/bin/Telmisartan_Structure_000.jpg" alt="Chemical Structure for Telmisartan" /></div></td></tr><tr><td headers="hd_b_ARBs.T1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Valsartan</td><td headers="hd_b_ARBs.T1_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135024022" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">144701-48-4</a></td><td headers="hd_b_ARBs.T1_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">C24-H29-N5-O3</td><td headers="hd_b_ARBs.T1_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><div class="graphic"><img src="/books/NBK548642/bin/Valsartan_Structure_000.jpg" alt="Chemical Structure for Valsartan" /></div></td></tr></tbody></table></div></div></div><div id="ARBs.ANNOTATED_BIBLIOGRAPHY"><h2 id="_ARBs_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 13 January 2017</p><ul class="first-line-outdent"><li><div class="bk_ref" id="ARBs.R1">Zimmerman HJ. Cardiovascular agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 623-5.<div><i>(Expert review of hepatotoxicity published in 1999; mentions a single case of hepatotoxicity from losartan with a positive rechallenge [Bosch 1997]).</i></div></div></li><li><div class="bk_ref" id="ARBs.R2">De Marzio DH, Navarro VJ. Antihypertensives. Hepatotoxicity of cardiovascular and antidiabetic medications. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 522-6.<div><i>(Review of hepatotoxicity of antihypertensive agents, mentions that cases of hepatotoxicity of candesartan, irbesartan, losartan and valsartan have been published, but none were fatal and were variable in both latency to onset [1 week to 6 months] and clinical presentation [cholestatic and hepatocellular]).</i></div></div></li><li><div class="bk_ref" id="ARBs.R3">Michel T, Hoffman BB. Treatment of myocardial ischemia and hypertension. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 745-88.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="ARBs.R4">Hillal-Dandan R. Nonpeptide angiotensin II receptor antagonists. Renin and angiotensin. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 736-9.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="ARBs.R5">Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793-5.  [<a href="/pubmed/7717281" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7717281</span></a>]<div><i>(Summary of adverse events during losartan therapy in prelicensure clinical trials in more than 2000 patients; most symptoms were no more frequent than with placebo; ALT elevations occurred in 1.9% of patients on losartan, but rates were similar in comparator arms).</i></div></div></li><li><div class="bk_ref" id="ARBs.R6">Nygaard B, Strandgaard S. Marked hepatotoxicity associated with losartan treatment. Blood Press 1996; 5: 190-1.  [<a href="/pubmed/8790930" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8790930</span></a>]<div><i>(Two women developed anicteric hepatitis on losartan: 55 year old developed back pain 3 weeks after starting losartan [bilirubin 1.3 mg/dL, ALT 650 U/L, Alk P 396 U/L], resolving within a month of stopping; 46 year old developed chest pain &#x0201c;a few months&#x0201d; after starting losartan [ALT 311 U/L, no bilirubin or Alk P given], resolving within 2 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="ARBs.R7">MacKay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996; 156: 278-85.  [<a href="/pubmed/8572837" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8572837</span></a>]<div><i>(In a controlled trial of losartan with or without hydrochlorothiazide [HCTZ] vs placebo in 703 patients with hypertension, there were no overall changes in serum aminotransferase levels or serious adverse events or dose modifications for any laboratory abnormality).</i></div></div></li><li><div class="bk_ref" id="ARBs.R8">Bosch X. Losartan-induced hepatotoxicity. JAMA 1997; 278: 1572.  [<a href="/pubmed/9370501" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9370501</span></a>]<div><i>(46 year old man developed jaundice one month after starting losartan [bilirubin 9.6 mg/dL, ALT 2574 U/L, Alk P 738 U/L], resolving within 4 months of stopping; 3 week rechallenge led to jaundice [Case 1 for losartan]; reply from Merck mentioning 80 reports of liver abnormalities among an estimated 2 million patients treated).</i></div></div></li><li><div class="bk_ref" id="ARBs.R9">Sever P, Holzgreve H. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension. J Human Hypertens 1997; 11 [Suppl 2]: S69-73.  [<a href="/pubmed/9331014" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9331014</span></a>]<div><i>(Analysis of two phase III trials [489 and 298 patients] of candesartan in hypertension for 6 to 12 months found low rate of side effects [headache and back pain most frequent] and &#x0201c;No clinically relevant changes in laboratory parameters [apart from two cases of increased hepatic enzymes]&#x0201d;).</i></div></div></li><li><div class="bk_ref" id="ARBs.R10">Andrade RJ, Lucena MI, Santalla F. Hepatic injury associated with losartan. Ann Pharmacother 1998; 32: 1371. <em>(77 year old man developed fatigue</em>. [<a href="/pubmed/9876824" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9876824</span></a>]<div><i>3 weeks after starting an excessive dose of losartan [150 mg daily] for hypertension [bilirubin 1.7 mg/dL, ALT 410 U/L, Alk P normal], resolving within 4 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="ARBs.R11">McClellan KJ, Goa KL. Candesartan cilexetil. A review of its use in essential hypertension. Drugs 1998; 56: 847-69.  [<a href="/pubmed/9829158" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9829158</span></a>]<div><i>(Review of pharmacology, clinical use and safety of candesartan: studies in 4147 patients given doses of 8 or 16 mg daily found low rate of adverse events, headache in 10%, cough in 1.6%, similar rates with placebo; ALT elevations occur in &#x0201c;occasional&#x0201d; patients, reported in 2 of 632 patients in one trial of candesartan given for 12 months).</i></div></div></li><li><div class="bk_ref" id="ARBs.R12">McClellan KJ, Balfour JA. Eprosartan. Drugs 1998; 55: 713-8.  [<a href="/pubmed/9585867" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9585867</span></a>]<div><i>(Review of pharmacology, clinical studies and safety of eprosartan; tolerability at doses of 400 to 1200 mg daily was similar to placebo: no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="ARBs.R13">McClellan KJ, Markham A. Telmisartan. Drugs 1998; 56: 1039-44.  [<a href="/pubmed/9878991" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9878991</span></a>]<div><i>(Review of pharmacology, clinical studies and safety of telmisartan; tolerability at doses of 20 to 160 mg daily was similar to placebo: no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="ARBs.R14">Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999; 21: 23-33.  [<a href="/pubmed/10433351" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10433351</span></a>]<div><i>(Review of safety and tolerability of different ARBs in clinical trials: &#x0201c;None of the compounds induced a clear, specific, dose dependent adverse effect that could be attributed to the drug": common complaints being headache, dizziness, and fatigue; ALT elevations occurred rarely and were transient and resolved despite continuation of therapy, only one case of ALT requiring discontinuation has been reported, with losartan and from the sponsor).</i></div></div></li><li><div class="bk_ref" id="ARBs.R15">Sega R. Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group. Blood Press 1999; 8: 114-21.  [<a href="/pubmed/10451039" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10451039</span></a>]<div><i>(Among 118 patients with hypertension treated with eprosartan or enalapril for 2 weeks, side effects were mild and similar in both groups; ALT results not given).</i></div></div></li><li><div class="bk_ref" id="ARBs.R16">Shusterman NH. Safety and efficacy of eprosartan, a new angiotensin II receptor blocker. Am Heart J 1999; 138 (3 Pt 2): 238-45.  [<a href="/pubmed/10467219" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10467219</span></a>]<div><i>(Review of clinical efficacy and safety of eprosartan; no mention of hepatotoxicity or ALT elevations).</i></div></div></li><li><div class="bk_ref" id="ARBs.R17">Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-45.  [<a href="/pubmed/10696996" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10696996</span></a>]<div><i>(Review of history, pharmacology, mechanism of action, clinical efficacy and safety of the angiotensin II receptor antagonists; &#x0201c;Occasional minor increases in liver enzymes were usually transient&#x0201d;).</i></div></div></li><li><div class="bk_ref" id="ARBs.R18">Hariraj R, Stoner E, Jader S, Preston DM. Drug points: prolonged cholestasis associated with irbesartan. BMJ 2000; 321: 547.  [<a href="/pmc/articles/PMC27470/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC27470</span></a>] [<a href="/pubmed/10968816" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10968816</span></a>]<div><i>(62 year old developed jaundice 1 month after starting irbesartan with bilirubin 23.6 mg/dL, AST 177 U/L, Alk P 3193 U/L, slow recovery, 2 biopsies).</i></div></div></li><li><div class="bk_ref" id="ARBs.R19">Gonz&#x000e1;lez-Jim&#x000e9;nez D, Varela JM, Calder&#x000f3;n E, Galindo J, Gonz&#x000e1;lez de la Puente MA. Candesartan and acute liver injury. Eur J Clin Pharmacol 2000; 56: 769-70.  [<a href="/pubmed/11214790" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11214790</span></a>]<div><i>(70 year old developed abdominal pain and jaundice 2 weeks after starting candesartan with bilirubin 21 mg/dL, ALT 244 U/L, Alk P 221 U/L, resolution in 2 months).</i></div></div></li><li><div class="bk_ref" id="ARBs.R20">Vallejo I, Garc&#x000ed;a Morillo S, Pamies E. [Acute hepatitis induced by candesartan]. Med Clin (Barc) 2000; 115: 719. Spanish.  [<a href="/pubmed/11141435" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11141435</span></a>]<div><i>(41 year old developed jaundice 5 weeks after starting candesartan [bilirubin 20 mg/dL, ALT 2700 U/L, Alk P 321 U/L], resolved with stopping).</i></div></div></li><li><div class="bk_ref" id="ARBs.R21">Markham A, Spencer CM, Jarvis B. Irbesartan: an updated review of its use in cardiovascular disorders. Drugs. 2000; 59: 1187-206.  [<a href="/pubmed/10852648" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10852648</span></a>]<div><i>(Review of pharmacology, clinical use and side effects of irbesartan; analysis of pooled data from 9 studies in 2606 patients found low rate of adverse events; no mention of hepatotoxicity or ALT elevations).</i></div></div></li><li><div class="bk_ref" id="ARBs.R22">Re&#x000f1;&#x000e9; JM, Buenestado J, Ses&#x000e9; E, Mi&#x000f1;ana JM. Acute hepatitis induced by valsartan. Med Clin (Barc) 2001; 117: 637-8.  [<a href="/pubmed/11714476" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11714476</span></a>]<div><i>(54 year old woman developed jaundice 18 weeks after starting valsartan for hypertension [bilirubin 23.6 mg/dL, ALT 1664 U/L, Alk P 385 U/L], resolving within 2 months of stopping).</i></div></div></li><li><div class="bk_ref" id="ARBs.R23">Chitturi S, Farrell GC. Drug-induced cholestasis. Semin Gastrointest Dis 2001; 12: 113-24.  [<a href="/pubmed/11352118" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11352118</span></a>]<div><i>(Review of the causes of drug induced liver injury with cholestatic features).</i></div></div></li><li><div class="bk_ref" id="ARBs.R24">Andrade RJ, Lucena MI, Fern&#x000e1;ndez MC, Vega JL, Garc&#x000ed;a-Cort&#x000e9;s M, Casado M, Guerrero-Sanchez E, et al. Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. Eur J Gastroenterol Hepatol 2002; 14: 887-90.  [<a href="/pubmed/12172412" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12172412</span></a>]<div><i>(56 year old man developed jaundice 8 days after starting irbesartan [bilirubin 7.5 to 16.1 mg/dL, ALT 2646 U/L, Alk P 305 U/L], with Alk P remaining elevated for 16 months, but biopsy not showing vanishing bile ducts).</i></div></div></li><li><div class="bk_ref" id="ARBs.R25">Tabak F, Mert A, Ozaras R, Biyikli M, Ozturk R, Ozbay G, Senturk H, et al. Losartan-induced hepatic injury. J Clin Gastroenterol 2002; 34: 585-6.  [<a href="/pubmed/11960076" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11960076</span></a>]<div><i>(52 year old woman developed jaundice 5 month after starting losartan [bilirubin not given, ALT 750 U/L], resolving after stopping but recurring within 2 weeks of restarting [bilirubin 8.9 mg/dL, ALT 941 U/L, Alk P 419 U/L], then resolving within 4 months of stopping).</i></div></div></li><li><div class="bk_ref" id="ARBs.R26">Basile G, Villari D, Gangemi S, Ferrara T, Accetta MG, Nicita-Mauro V. Candesartan cilexetil-induced severe hepatotoxicity. J Clin Gastroenterol 2003; 36: 273-5.  [<a href="/pubmed/12590242" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12590242</span></a>]<div><i>(61 year old woman developed fever, abdominal pain and jaundice 1 month after starting candesartan [bilirubin 27.2 rising to 46.8 mg/dL, ALT 918 U/L, Alk P 142 U/L], resolving in 8 weeks with prednisone therapy, biopsy showing bile duct loss and fibrosis: Case 1 of candesartan).</i></div></div></li><li><div class="bk_ref" id="ARBs.R27">Kiykim A, Altintas E, Sezgin O, Sezer K, Tiftik N, Akbay E, Seyrek E, et al. Valsartan-induced hepatotoxicity in a HBsAg-Positive patient. Am J Gastroenterol 2003; 98: 507.  [<a href="/pubmed/12591083" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12591083</span></a>]<div><i>(52 year old woman with hypertension and HBsAg without chronic ALT elevations developed jaundice 4 weeks after starting valsartan [peak bilirubin 7.8 mg/dL, ALT 780 U/L, Alk P 1840 U/L], resolving within 3 months of stopping).</i></div></div></li><li><div class="bk_ref" id="ARBs.R28">Foruny Olcina JR, Moreira Vicente VF, G&#x000f3;mez Garc&#x000ed;a M, Morell Hita JL. [Irbesartan-induced acute hepatitis] Gastroenterol Hepatol 2004; 27: 71-2. Spanish.  [<a href="/pubmed/14733885" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14733885</span></a>]<div><i>(59 year old developed jaundice 2 weeks after starting irbesartan [bilirubin 8.5 mg/dL, ALT 1378 U/L, Alk P 244 U/L], slow resolution over 4 months).</i></div></div></li><li><div class="bk_ref" id="ARBs.R29">P&#x000e9;ron JM, Robic MA, Bureau C, Vinel JP. [Irbesartan induced acute hepatitis: one case]. Gastroenterol Clin Biol 2005; 29: 747-8. French.  [<a href="/pubmed/16149188" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16149188</span></a>]<div><i>(51 year old woman with fatty liver developed urticaria and myalgias 3 weeks after starting irbesartan [ALT 890 U/L, Alk P and bilirubin not given], resolving within 2-3 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="ARBs.R30">Annicchiarico BE, Siciliano M. Could irbesartan trigger autoimmune cholestatic hepatitis? Eur J Gastroenterol Hepatol 2005; 17: 247-8.  [<a href="/pubmed/15674105" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15674105</span></a>]<div><i>(69 year old man developed jaundice 1 month after starting irbesartan [bilirubin 31.9 mg/dL, ALT 1449 U/L, Alk P 515 U/L, ANA negative and normal IgG], responsing to corticosteroids, but relapsing on stopping, but then resolving without relapse after 2 years of corticosteroid therapy, still autoantibody negative).</i></div></div></li><li><div class="bk_ref" id="ARBs.R31">White WB, Punzi HA, Murwin D, Koval SE, Davidai G, Neutel JM. Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension. J Clin Hypertens(Greenwich) 2006; 8: 626-33.  [<a href="/pubmed/16957424" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16957424</span></a>]<div><i>(Among 1109 patients with hypertension treated with either telmisartan or valsartan or placebo, therapy was well tolerated; no mention of ALT levels or liver injury).</i></div></div></li><li><div class="bk_ref" id="ARBs.R32">Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug-induced liver injury in the United States. Liver Transpl 2004; 10: 1018-23.  [<a href="/pubmed/15390328" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15390328</span></a>]<div><i>(Among ~50,000 liver transplants done in the United States between 1990 and 2002, 270 [0.5%] were done for drug induced acute liver failure, but no case was attributed to an angiotensin receptor blocker).</i></div></div></li><li><div class="bk_ref" id="ARBs.R33">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34. <em>(Among 300 </em>. [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>cases of drug induced liver disease in the US collected from 2004 to 2008, no cases were attributed to an angiotensin receptor blocker).</i></div></div></li><li><div class="bk_ref" id="ARBs.R34">Schumacher H, Mancia G. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press Suppl 2008; 1: 32-40.  [<a href="/pubmed/18705533" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18705533</span></a>]<div><i>(Among all patients enrolled in 50 clinical trials of telmisartan [~8000] alone or in combination with HCTZ, "hepatobiliary system disorders" developed in 0.1% of patients and changes in liver enzymes in &#x0003c;0.1%, but no details or definitions given).</i></div></div></li><li><div class="bk_ref" id="ARBs.R35">Chrysant SG, Oparil S, Melino M, Karki S, Lee J, Heyrman R. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens(Greenwich) 2009; 11: 475-82.  [<a href="/pubmed/19751459" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19751459</span></a>]<div><i>(Among 1940 patients with hypertension treated for 8 weeks with varying combinations of olmesartan, amlodipine and placebo, safety and tolerability were comparable among groups: no mention of ALT elevations or liver injury).</i></div></div></li><li><div class="bk_ref" id="ARBs.R36">Destro M, Preti P, D'Ospina A, Christian Achiri NN, Ricci AR, Cagnoni F. Olmesartan medoxomil: recent clinical and experimental acquisitions. Expert Opin Drug Metab Toxicol 2009; 5: 1149-57.  [<a href="/pubmed/19689219" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19689219</span></a>]<div><i>(Review of olmesartan, 7th ARB approved for use in the United States, given as a medoxomil prodrug which is esterified during absorption; not metabolized by P450 system and rates of side effects are similar to those with placebo and include headache, dizziness and flu-like symptoms; no mention of ALT elevations or liver toxicity).</i></div></div></li><li><div class="bk_ref" id="ARBs.R37">Punzi HA. Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Rev Cardiovasc Ther 2009; 7: 229-39.  [<a href="/pubmed/19296759" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19296759</span></a>]<div><i>(Review of olmesartan, a specific inhibitor of the angiotensin II type 1 receptor [AT1] taken as a medoxomil prodrug, few drug-drug interactions, effective alone or in combinations, particularly with hydrochlorothiazide, well tolerated with only slightly increased frequency of side effects compared to placebo [dizziness]; no mention of ALT elevations or liver toxicity).</i></div></div></li><li><div class="bk_ref" id="ARBs.R38">Drugs for hypertension. Treat Guidel Med Lett 2009; 7: 1-10.  [<a href="/pubmed/19107095" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19107095</span></a>]<div><i>(Brief overview of drugs for hypertension with guidelines on their use with information on prices and toxicities, mentions that side effects of angiotensin II receptor antagonists are similar to those of ACE inhibitors but they do not cause cough and only rarely cause angioedema, loss of taste and hepatoxicity).</i></div></div></li><li><div class="bk_ref" id="ARBs.R39">Jim&#x000e9;nez-S&#x000e1;enz M, Arroyo Q, Sanjuan M, Herrer&#x000ed;as JM. [Candesartan-induced cholestatic hepatitis: a case report]. Gastroenterol Hepatol 2010; 33: 66-7. Spanish.  [<a href="/pubmed/19713003" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19713003</span></a>]<div><i>(82 year old man developed jaundice 3 weeks after starting candesartan [bilirubin 6.8 rising to 22.2 mg/dL, ALT 272 U/L, Alk P 1045 U/L], resolving 8 weeks after stopping with prednisone therapy).</i></div></div></li><li><div class="bk_ref" id="ARBs.R40">Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76.  [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, two of which were atttributed to antihypertensive agents [hydralazine and methyldopa], but none to angiotensive II receptor blockers).</i></div></div></li><li><div class="bk_ref" id="ARBs.R41">Oertelt-Prigione S, Crosignani A, Gallieni M, Vassallo E, Podda M, Zuin M. Severe hepatic encephalopathy in a patient with liver cirrhosis after administration of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy: a case report. J Med Case Reports 2010; 4: 141.  [<a href="/pmc/articles/PMC2890618/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2890618</span></a>] [<a href="/pubmed/20482828" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20482828</span></a>]<div><i>(40 year old man with cirrhosis and nephrotic syndrome developed coma within a day of adding ramipril to losartan, therapy with marked elevation in ammonia levels, recovery within days of stopping and recurrence on restarting the combination).</i></div></div></li><li><div class="bk_ref" id="ARBs.R42">Taglietti F, Del Nonno F, Baiocchini A, Falasca L, Pieri S, Capone A, Grilli E, et al. Acute hepatocellular and cholestatic injury during therapy with hydrochlorothiazide - clinicohistopathologic findings: a case report. J Med Case Rep 2010; 4: 332.  [<a href="/pmc/articles/PMC2978230/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2978230</span></a>] [<a href="/pubmed/20964809" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20964809</span></a>]<div><i>(68 year old man developed fatigue and jaundice 10 days after starting hydrochlorothiazide and olmesartan [bilirubin 6.3 rising to 14.7 mg/dL, ALT 346 U/L, Alk P 1091 U/L], resolving within 3 months of stopping both drugs).</i></div></div></li><li><div class="bk_ref" id="ARBs.R43">Baker WL, White WB. Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension. Ann Pharmacother 2011; 45: 1506-15.  [<a href="/pubmed/22116996" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22116996</span></a>]<div><i>(Systematic review of literature on safety and efficacy of azilsartan identified 3 full publications and 5 abstracts describing clinical trials; "Other laboratory findings, such as increases in serum creatinine or liver enzyme levels, occurred infrequently and at similar rates between all groups"; no mention of hepatotoxicity or clinically apparent liver injury).</i></div></div></li><li><div class="bk_ref" id="ARBs.R44">Azilsartan medoxomil (Edarbi) the eighth ARB. Med Lett Drugs Ther 2011; 53(1364): 39-40. (Concise summary of the clinical efficacy, safety and costs of azilsartan shortly after its approval in the US; hepatotoxicity was not mentioned). [<a href="/pubmed/21566544" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21566544</span></a>]</div></li><li><div class="bk_ref" id="ARBs.R45">Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, Wu TT, Murray JA. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 2012: 87: 732-8.  [<a href="/pmc/articles/PMC3538487/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3538487</span></a>] [<a href="/pubmed/22728033" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22728033</span></a>]<div><i>(Clinical description of 22 patients with suspected olmesartan induced enteropathy, ages 47 to 81 years, presenting with chronic diarrhea, weight loss and fatigue arising 0.5-7 years after starting olmesartan, with villous flattening and atrophy on intestinal biopsy, lack of anti-endomyoseal and transglutaminase antibodies, not respondive to a gluten-free diet, but resolving promptly on stopping olmesartan and subsequent improvement in intestinal histology and ability to tolerate reintroduction of gluten).</i></div></div></li><li><div class="bk_ref" id="ARBs.R46">Bj&#x000f6;rnsson ES, Bergmann OM, Bj&#x000f6;rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-25.  [<a href="/pubmed/23419359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, but none were attributed to antihypertensive agents or to angiotensin II receptor blockers).</i></div></div></li><li><div class="bk_ref" id="ARBs.R47">Cyrany J, Vasatko T, Machac J, Nova M, Szanyi J, Kopacova M. Letter: telmisartan-associated enteropathy - is there any class effect? Aliment Pharmacol Ther 2014; 40: 569-70. 25103353. [<a href="/pubmed/25103353" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25103353</span></a>]<div><i>(71 year old woman developed diarrhea, weight loss, and duodenal villous atrophy, arising 2 months after starting telmisasrtan and resolving with stopping and without gluten withdrawal; no mention of liver test results).</i></div></div></li><li><div class="bk_ref" id="ARBs.R48">Ianiro G, Bibb&#x000f2; S, Montalto M, Ricci R, Gasbarrini A, Cammarota G. Systematic review: Sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther 2014; 40: 16-23.  [<a href="/pubmed/24805127" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24805127</span></a>]<div><i>(Systematic review of 11 publications on olmesartan associated enteropathy in 54 patients, ages 47 to 87 years, half women, arising 6 months to 7 years after starting drug, marked by villous flattening and atrophy, absence of typical celiac-associated autoantibodies, non-response to gluten free diet, but prompt resolution with stopping olmesartan).</i></div></div></li><li><div class="bk_ref" id="ARBs.R49">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. Ann Hepatol 2014; 13: 231-9.  [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i> (Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, none of which were attributed to an angiotensin II receptor blocker).</i></div></div></li><li><div class="bk_ref" id="ARBs.R50">Al-Halawani MZ, Thawabi M, Asslo F, Shaaban H, Shamoon F, Baddoura WJ. Losartan-induced ischemic hepatocellular hepatotoxicity: a case report and literature review. J Family Med Prim Care 2014; 3: 272-4.  [<a href="/pmc/articles/PMC4209687/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4209687</span></a>] [<a href="/pubmed/25374869" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25374869</span></a>]<div><i> (65 year old woman developed abdominal pain and anusea 4 months after starting losartan for hypertension [bilirubin 2.7 mg/dL, ALT 1184 U/L, Alk P 142 U/L], with rapid improvement within 1-2 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="ARBs.R51">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52.  [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i> (Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 39 were attributed to antihypertensive medications including one each to losartan, irbesartan and valsartan).</i></div></div></li><li><div class="bk_ref" id="ARBs.R52">Negro A, Rossi GM, Santi R, Iori V, De Marco L. A case of severe sprue-like enteropathy associated with losartan. J Clin Gastroenterol 2015; 49: 794.  [<a href="/pubmed/26166143" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26166143</span></a>]<div><i> (A 69 year old man developed chronic diarrhea, weight loss, anemia and low albumin, 3 years after starting losartan for hypertension with prompt resolution on stopping; no mention of liver test results).</i></div></div></li><li><div class="bk_ref" id="ARBs.R53">Herman ML, Rubio-Tapia A, Wu TT, Murray JA. A case of severe sprue-like enteropathy associated with valsartan. ACG Case Rep J 2015; 2: 92-4.  [<a href="/pmc/articles/PMC4435362/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4435362</span></a>] [<a href="/pubmed/26157924" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26157924</span></a>]<div><i>(71 year old woman with long history of refractory sprue unresponsive to gluten withdrawal had a prompt remission when valsartan was discontinued [duration of therapy not provided]; no mention of liver test abnormalities).</i></div></div></li><li><div class="bk_ref" id="ARBs.R54">Non-Alcoholic Fatty Liver Disease Study Group, Dolci M, Nascimbeni F, Romagnoli D, Reggiani Bonetti L, Guaraldi G, Mascia MT, Lonardo A. Nonalcoholic steatohepatitis heralding olmesartan-induced sprue-like enteropathy. Dig Liver Dis 2016; 48: 1399-1401.  [<a href="/pubmed/27486047" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27486047</span></a>]<div><i>(72 year old man developed fatigue and diarrhea 3 years after starting olmesartan [ALT 202, Alk P and bilirubin not given, liver biopsy showing steatosis, duodenal biopsy partial villous atrophy], with prompt resolution of ALT elevations and diarrhea within 3 weeks of stopping olmesartan).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548642</span><span class="label">PMID: <a href="/pubmed/31643954" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643954</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/GeneralAnesthetics/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/ACEinibitors/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548642&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548642/?report=reader">PubReader</a></li><li><a href="/books/NBK548642/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548642" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548642" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Angiotensin II Receptor Antagonists. [Updated 2017 Jan 13].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548642/pdf/Bookshelf_NBK548642.pdf">PDF version of this page</a> (156K)</li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=(Angiotensinr+II+Receptor+Antagonists)+AND+Human%5BMH%5D+AND+(jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Angiotensin II Receptor Antagonists: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=(Angiotensinr+II+Receptor+Antagonists)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Angiotensin II Receptor Antagonists: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4856996" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4856996" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4856996" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/10854085" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.</a><span class="source">[J Hum Hypertens. 2000]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Israili ZH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Hum Hypertens. 2000 Apr; 14 Suppl 1:S73-86. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31471672" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Association of sprue-like enteropathy and angiotensin receptor-1 antagonists.</a><span class="source">[Wien Klin Wochenschr. 2019]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Association of sprue-like enteropathy and angiotensin receptor-1 antagonists.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wenzel RR, Datz C. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Wien Klin Wochenschr. 2019 Oct; 131(19-20):493-501. Epub 2019 Aug 30.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31217979" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review.</a><span class="source">[Gastroenterol Rep (Oxf). 2019]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kamal A, Fain C, Park A, Wang P, Gonzalez-Velez E, Leffler DA, Hutfless SM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Gastroenterol Rep (Oxf). 2019 Jun; 7(3):162-167. Epub 2019 Jun 1.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27210827" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice.</a><span class="source">[J Mol Cell Cardiol. 2016]</span><div class="brieflinkpop offscreen_noflow">The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wang X, Ye Y, Gong H, Wu J, Yuan J, Wang S, Yin P, Ding Z, Kang L, Jiang Q, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Mol Cell Cardiol. 2016 Aug; 97:180-90. Epub 2016 May 19.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31401939" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> The place of ARBs in heart failure therapy: is aldosterone suppression the key?</a><span class="source">[Ther Adv Cardiovasc Dis. 2019]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> The place of ARBs in heart failure therapy: is aldosterone suppression the key?<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Markan U, Pasupuleti S, Pollard CM, Perez A, Aukszi B, Lymperopoulos A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Ther Adv Cardiovasc Dis. 2019 Jan-Dec; 13:1753944719868134. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643954" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643954" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=604676b0ddcb804c59ac6b21">Angiotensin II Receptor Antagonists - LiverTox</a><div class="ralinkpop offscreen_noflow">Angiotensin II Receptor Antagonists - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:10:40-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal102&amp;ncbi_phid=CE899CA6046738D10000000000A9003C&amp;ncbi_session=CE899CA604676AF1_0169SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548642%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548642&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548642/&amp;ncbi_pagename=Angiotensin II Receptor Antagonists - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE899CA604676AF1_0169SID /projects/books/PBooks@9.2 portal102 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>